StockDriftsStockDriftsEnzychem Life Science (183490) has 10 disclosed insider purchases and 4 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩67M ($47K) in reported transaction value. The earliest filing StockDrifts holds for Enzychem Life Science is dated 2024-02-14; the most recent is 2026-03-31. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -11.07%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-07-23 | BUY | 신규선임 | 김진원 Jinwon Kim | Internal director | 55.0K | ₩990 | +0.0% | ₩54M ($38K) |
| 2026-03-31 | BUY | 신규선임 | 구병주 Koo Byeong-ju | Outside Director | 7.2K | ₩990 | +0.0% | ₩7M ($5K) |
| 2024-08-23 | SELL | Market Sell | 윤영배 Youngbae Yoon | vice president | -1 | ₩1,602 | +14.5% | ₩2K ($1) |
| 2024-08-23 | SELL | Market Sell | 윤영배 Youngbae Yoon | vice president | -5.0K | ₩1,602 | +14.5% | ₩8M ($6K) |
| 2024-08-23 | BUY | Market Buy | 윤영배 Youngbae Yoon | vice president | 8.0K | ₩1,602 | -14.5% | ₩13M ($9K) |
| 2024-08-23 | SELL | Market Sell | 윤영배 Youngbae Yoon | vice president | -1 | ₩1,602 | +14.5% | ₩2K ($1) |
| 2024-08-23 | SELL | Market Sell | 윤영배 Youngbae Yoon | vice president | -3.0K | ₩1,602 | +14.5% | ₩5M ($3K) |
| 2024-06-11 | BUY | Market Buy | 윤영배 Youngbae Yoon | vice president | 1.6K | ₩1,897 | -27.8% | ₩3M ($2K) |
| 2024-05-30 | BUY | Market Buy | 윤영배 Youngbae Yoon | vice president | 2.0K | ₩1,965 | -30.3% | ₩4M ($3K) |
| 2024-04-18 | BUY | Market Buy | 윤영배 Youngbae Yoon | vice president | 1.7K | ₩1,760 | -22.2% | ₩3M ($2K) |
| 2024-03-29 | BUY | Market Buy | 최재호 Jaeho Choi | Managing Director | 4.7K | ₩1,883 | -27.2% | ₩9M ($6K) |
| 2024-03-06 | BUY | Market Buy | 윤영배 Youngbae Yoon | vice president | 2.5K | ₩1,600 | -14.4% | ₩4M ($3K) |
| 2024-02-26 | BUY | Market Buy | 정재한 Jaehan Jeong | Managing Director | 6.2K | ₩1,651 | -17.0% | ₩10M ($7K) |
| 2024-02-22 | BUY | Market Buy | 김동성 Kim Dong-seong | vice president | 500 | ₩1,663 | -17.6% | ₩832K ($577) |
| 2024-02-20 | BUY | Market Buy | 김동성 Kim Dong-seong | vice president | 3.8K | ₩1,718 | -20.3% | ₩7M ($5K) |
| 2024-02-14 | BUY | Market Buy | 최재호 Jaeho Choi | Managing Director | 570 | ₩1,750 | -21.7% | ₩998K ($693) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Enzychem Life Science. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.